USA flag logo/image

An Official Website of the United States Government

Percutaneously-Placed Blood Flow Measuring System

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96368
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
HL104812
Solicitation Year:
N/A
Solicitation Topic Code:
NHLBI
Solicitation Number:
N/A
Small Business Information
DVX, LLC
31 AIRPARK RD Princeton, NJ -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Percutaneously-Placed Blood Flow Measuring System
Agency: HHS
Contract: 1R43HL104812-01
Award Amount: $130,342.00
 

Abstract:

DESCRIPTION (provided by applicant): This research is to develop a minimally invasive, percutaneously-placed system that will measure blood flow in the body. Blood flow keeps tissue alive. Sophisticated instruments, such as duplex Doppler, MRI or CT angiog raphy, can measure blood flow noninvasively, but provide only a snapshot of the flow. Our goal is to develop minimally invasive percutaneously-placed devices that can provide both acute and long-term reliable, accurate monitoring of blood flow, thus prov iding new medically significant information about patients' cardiovascular systems. We have previously developed, under NIH sponsorship, an implant unit to operate a surgically implanted flow sensor in an artificial artery, and wirelessly transmit the flo w data transcutaneously. Under another NIH-sponsored program, we have learned how to make special flexible ultrasound Doppler transducer systems. In this Phase I, we will measure flow by holding these transducers against the inside wall of an artery with a stent, with signals to and from the transducers carried by a thin, narrow strip lying along the wall. In Phase I, the intravascular lead will exit the animal body for signal processing. In the future, for long-term measurements, these signals will conne ct to an implanted unit for transcutaneous communication. Collaborating with us are an outstanding cardiac surgeon and interventional cardiologist who will perform the surgical studies and advise the team on percutaneously placing stent-devices. The effec ts of neointimal growth and tissue response on these new components, and any effects of these components on vessel tissue, will be evaluated by a 30-day implant followed by histopathological examination of the vessel. Where flow monitoring has been possib le, as in dialysis access grafts and leg bypass grafts, long-term monitoring of flow has significantly improved patient outcomes. The goals of this program are to prove the concept of a new percutaneously placed blood flow measuring system to bring the ben efits of flow monitoring to many parts of the circulatory system, potentially greatly improving outcomes for millions of patients. PUBLIC HEALTH RELEVANCE: This research is to develop a minimally invasive implantable device that can provide both sho rt and long-term reliable, accurate monitoring of blood flow, thus providing new medically significant information about a patient's cardiovascular system. Since blood flow keeps tissue alive, it may be possible to prevent failures of blood flow, such as h eart attacks, and bring the benefits of flow monitoring to many parts of the circulatory system, significantly improving outcomes for millions of patients.

Principal Investigator:

David Vilkomerson
6099243590
DV1DVX@COMCAST.NET

Business Contact:


dv1dvx@comcast.net
Small Business Information at Submission:

DVX, LLC
DVX, LLC 31 AIRPARK RD Princeton, NJ 08540

EIN/Tax ID: 122384218
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No